Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report

Cannabis sativa: a planta que pode produzir efeitos indesejáveis e também tratá-los

(2011) Antonio Waldo Zuardi et al.   REVISTA BRASILEIRA DE PSIQUIATRIA

Neuroimaging in social anxiety disorder: A systematic review of the literature

(2010) Maria Cecilia Freitas-Ferrari et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Instituto Nacional de Ciência e Tecnologia em Medicina Translacional (INCT-TM): abordagens metodológicas

(2010) Jaime E. C. Hallak et al.   REVISTA BRASILEIRA DE PSIQUIATRIA

Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)

(2010) Jaime E. C. Hallak et al.   REVISTA BRASILEIRA DE PSIQUIATRIA

Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing

(2009) Paolo Fusar-Poli et al.   ARCHIVES OF GENERAL PSYCHIATRY

5-HT1Areceptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats

(2009) Leonardo B.M. Resstel et al.   BRITISH JOURNAL OF PHARMACOLOGY

Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors

(2009) TV Zanelati et al.   BRITISH JOURNAL OF PHARMACOLOGY

Study of the psychometric qualities of the Brief Social Phobia Scale (BSPS) in Brazilian university students

(2009) F.L. Osório et al.   EUROPEAN PSYCHIATRY

Cannabis and anxiety: a critical review of the evidence

(2009) José Alexandre Crippa et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Magnetic resonance spectroscopy in anxiety disorders

(2008) Clarissa Trzesniak et al.   ACTA NEUROPSYCHIATRICA

Neural Basis of Δ-9-Tetrahydrocannabinol and Cannabidiol: Effects During Response Inhibition

(2008) Stefan J. Borgwardt et al.   BIOLOGICAL PSYCHIATRY

Cannabidiol was ineffective for manic episode of bipolar affective disorder

(2008) AW Zuardi et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Cannabidiol for the treatment of psychosis in Parkinson’s disease

(2008) AW Zuardi et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Influence of escitalopram treatment on 5-HT1A receptor binding in limbic regions in patients with anxiety disorders

(2008) C Spindelegger et al.   MOLECULAR PSYCHIATRY

Comparability Between Telephone and Face-to-Face Structured Clinical Interview forDSM-IVin Assessing Social Anxiety Disorder

(2008) José Alexandre S. Crippa et al.   PERSPECTIVES IN PSYCHIATRIC CARE

Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats

(2008) Alline Cristina Campos et al.   PSYCHOPHARMACOLOGY

Structural magnetic ressonance imaging in anxiety disorders: an update of research findings

(2008) Maria Cecília Freitas Ferrari et al.   REVISTA BRASILEIRA DE PSIQUIATRIA

Cross- cultural validation of the Brazilian Portuguese version of the Social Phobia Inventory (SPIN): study of the items and internal consistency

(2008) Flávia de Lima Osório et al.   REVISTA BRASILEIRA DE PSIQUIATRIA

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action

(2008) Antonio Waldo Zuardi   REVISTA BRASILEIRA DE PSIQUIATRIA

The diverse CB1and CB2receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin

(2007) R G Pertwee   BRITISH JOURNAL OF PHARMACOLOGY

Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro

(2007) A Thomas et al.   BRITISH JOURNAL OF PHARMACOLOGY

Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence

(2007) Julia D. Buckner et al.   JOURNAL OF PSYCHIATRIC RESEARCH